• Contact Us
  • twitter
  • facebook
  • linkedin
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Science
    • Overview
    • Neuromodulation: CA8 Platform
    • Revolutionizing Gene Therapy
    • Chronic Pain Treatment Innovation
    • Publications
    • Collaborators & Patents
  • Our Pipeline
    • Overview
    • ADB-101 Erythromelalgia
    • ADB-102 OA Knee Pain
    • ADB-103 OA Hip Pain
    • ADB-104 Epilepsy
    • ADB-105 Hearing Loss
    • ADB-106 Ophthalmology
  • The Pain Problem
    • Chronic Pain
    • Opioid Crisis
  • Partnering
  • News & Events
    • Press Releases
    • Events
    • Alerts

Hello world!

by AdoloreJTC24 | Feb 7, 2024 | Uncategorized | 0 comments

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Adolore BioTherapeutics Announces FDA Orphan Drug Designation for its Kv7-activating rdHSV-CA8* Therapy in the Treatment of Erythromelalgia
  • Dr. Roy Levitt, Executive Chairman of Adolore BioTherapeutics, Presented at the Next Generation Gene Therapy Vectors Summit
  • Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
  • Adolore BioTherapeutics to Present at Festival of Biologics USA 2025
  • Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting

Recent Comments

No comments to show.
Delray Beach, FL 33446, USA
Sign Up!
Stay up to date and get
notifications via email
when we post updates

Company Contact:

info@adolore.com

© 2026  Adolore BioTherapeutics.  All rights reserved.             Privacy Policy               Terms  and Conditions